| FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer N Turner, A Pearson, R Sharpe, M Lambros, F Geyer, MA Lopez-Garcia, ... Cancer research 70 (5), 2085-2094, 2010 | 819 | 2010 |
| Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor–positive breast cancer MT Herrera-Abreu, M Palafox, U Asghar, MA Rivas, RJ Cutts, ... Cancer research 76 (8), 2301-2313, 2016 | 659 | 2016 |
| Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer G Schiavon, S Hrebien, I Garcia-Murillas, RJ Cutts, A Pearson, ... Science translational medicine 7 (313), 313ra182-313ra182, 2015 | 581 | 2015 |
| Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets N Turner, MB Lambros, HM Horlings, A Pearson, R Sharpe, R Natrajan, ... Oncogene 29 (14), 2013-2023, 2010 | 463 | 2010 |
| High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial A Pearson, E Smyth, IS Babina, MT Herrera-Abreu, N Tarazona, C Peckitt, ... Cancer discovery 6 (8), 838-851, 2016 | 262 | 2016 |
| Single-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast cancer US Asghar, AR Barr, R Cutts, M Beaney, I Babina, D Sampath, J Giltnane, ... Clinical Cancer Research 23 (18), 5561-5572, 2017 | 243 | 2017 |
| Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer N Chopra, H Tovey, A Pearson, R Cutts, C Toms, P Proszek, M Hubank, ... Nature communications 11 (1), 2662, 2020 | 194 | 2020 |
| FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo R Sharpe, A Pearson, MT Herrera-Abreu, D Johnson, A Mackay, JC Welti, ... Clinical Cancer Research 17 (16), 5275-5286, 2011 | 192 | 2011 |
| ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment MT Dillon, KF Bergerhoff, M Pedersen, H Whittock, E Crespo-Rodriguez, ... Clinical Cancer Research 25 (11), 3392-3403, 2019 | 166 | 2019 |
| Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer MT Herrera-Abreu, A Pearson, J Campbell, SD Shnyder, MA Knowles, ... Cancer discovery 3 (9), 1058-1071, 2013 | 131 | 2013 |
| Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance A Pearson, P Proszek, J Pascual, C Fribbens, MK Shamsher, B Kingston, ... Clinical Cancer Research 26 (3), 608-622, 2020 | 105 | 2020 |
| The role played by endocytosis in albumin-induced secretion of TGF-β1 by proximal tubular epithelial cells R Diwakar, AL Pearson, P Colville-Nash, NJ Brunskill, MEC Dockrell American Journal of Physiology-Renal Physiology 292 (5), F1464-F1470, 2007 | 79 | 2007 |
| Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours. EC Smyth, NC Turner, C Peckitt, A Pearson, G Brown, S Chua, ... Journal of Clinical Oncology 33 (15_suppl), 2508-2508, 2015 | 52 | 2015 |
| Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study R Hui, A Pearson, J Cortes, C Campbell, C Poirot, HA Azim Jr, ... Clinical Cancer Research 26 (2), 354-363, 2020 | 50 | 2020 |
| Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers J Pascual, JSJ Lim, IR Macpherson, AC Armstrong, A Ring, AFC Okines, ... Cancer discovery 11 (1), 92-107, 2021 | 48 | 2021 |
| An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer I Garcia-Murillas, R Sharpe, A Pearson, J Campbell, R Natrajan, ... Oncogene 33 (19), 2478-2486, 2014 | 36 | 2014 |
| Albumin induces interleukin-6 release from primary human proximal tubule epithelial cells. AL Pearson, P Colville-Nash, JT Kwan, ME Dockrell Journal of nephrology 21 (6), 887-893, 2008 | 23 | 2008 |
| Identification of subtypes of triple negative breast cancer (TNBC) that are sensitive to CDK4/6 inhibition. U Asghar, MT Herrera-Abreu, R Cutts, I Babina, A Pearson, NC Turner Journal of Clinical Oncology 33 (15_suppl), 11098-11098, 2015 | 22 | 2015 |
| Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results. EC Smyth, NC Turner, A Pearson, C Peckitt, I Chau, DJ Watkins, ... Journal of Clinical Oncology 34 (4_suppl), 154-154, 2016 | 20 | 2016 |
| Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline PTEN Mutations B Kingston, C Bailleux, S Delaloge, G Schiavon, V Scott, M Lacroix-Triki, ... JCO precision oncology 3, 1-7, 2019 | 16 | 2019 |
Rachael NatrajanThe Institute of Cancer ResearchVerified email at icr.ac.uk
